Genetic and genomic approaches to the detection of heart transplant rejection

Personalized Medicine

Volumn 9, Issue 7, 2012, Pages 693-705

  Kransdorf, Evan P ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

antibody mediated rejection; cellular rejection; endomyocardial biopsy; gene expression profiling; genomics; heart transplantation; mycophenolate mofetil; pharmacogenomics; tacrolimus

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; CYTOCHROME P450 3A5; GAMMA INTERFERON; GLYCOPROTEIN P; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; MICRORNA 155; MICRORNA 223; MULTIDRUG RESISTANCE PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICAN; AGE; CARDIAC GRAFT REJECTION; CLINICAL FEATURE; COPY NUMBER VARIATION; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; ECHOCARDIOGRAPHY; EPIGENETICS; GENE DELETION; GENE EXPRESSION PROFILING; GENE INSERTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; GENOMICS; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; METABOLOMICS; PERICARDIAL EFFUSION; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RNA EXTRACTION; RNA INTERFERENCE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; TRICUSPID VALVE REGURGITATION;

EID: 84866412431     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.84     Document Type: Review

References (83)

1. Stehlik J, Edwards LB, Kucheryavaya AY et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report-2011. J. Heart Lung Transplant. 30(10), 1078-1094 (2011).
2. Kapp C. Heart transplant recipient climbs the Matterhorn. Lancet 362(9387), 880-881 (2003).
3. Haykowsky MJ, Riess K, Burton I, Jones L, Tymchak W. Heart transplant recipient completes ironman triathlon 22 years after surgery. J. Heart Lung Transplant. 28(4), 415 (2009).
4. Sprangers B, Kuypers DR, Vanrenterghem Y. Immunosuppression: does one regimen fit all? Transplantation 92(3), 251-261 (2011).
5. Caves PK, Stinson EB, Billingham ME, Rider AK, Shumway NE. Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J. Thorac. Cardiovasc. Surg. 66(3), 461-466 (1973).
6. Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J. Hum. Genet. 54(1), 15-39 (2009).
7. Jarcho J, Naftel DC, Shroyer TW et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group. J. Heart Lung Transplant. 13(4), 583-595; discussion 595-596 (1994).
8. Kaczmarek I, Deutsch MA, Rohrer ME et al. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? J. Heart Lung Transplant. 25(9), 1057-1062 (2006).
9. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant. 6(6), 1377-1386 (2006).
10. Kirklin JK, Naftel DC, Bourge RC et al. Rejection after cardiac transplantation. A time-related risk factor analysis. Circulation 86(5 Suppl.), II236-II241 (1992).
11. Lietz K, John R, Kocher A et al. Increased prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients. Circulation 104(90001), I177-I183 (2001).
12. Stoica SC, Cafferty F, Pauriah M et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J. Heart Lung Transplant. 25(4), 420-425 (2006).
13. Kobashigawa JA, Kirklin JK, Naftel DC et al. Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group. J. Heart Lung Transplant. 12(3), 355-366 (1993).
14. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 93(1), 1-10 (2012).
15. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24(11), 1710-1720 (2005).
16. Brunner-La Rocca HP, Sütsch G, Schneider J, Follath F, Kiowski W. Natural course of moderate cardiac allograft rejection (International Society for Heart Transplantation grade 2) early and late after transplantation. Circulation 94(6), 1334-1338 (1996).
17. Milano A, Caforio AL, Livi U et al. Evolution of focal moderate (International Society for Heart and Lung Transplantation grade 2) rejection of the cardiac allograft. J. Heart Lung Transplant. 15(5), 456-460 (1996).
18. Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J. Heart Transplant. 8(6), 430-443 (1989).
19. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 30(3), 252-269 (2011).
20. Tadwalkar R, Patel J, Kittleson M, Czer L, Kobashigawa J. Consequences of first-year rejection after heart transplantation: is the worst yet to come? J. Am. Coll. Cardiol. 59(13), e992 (2012).
21. Kfoury AG, Snow GL, Budge D et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 31(1), 46-51 (2012).
22. Berry GJ, Angelini A, Burke MM et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011). J. Heart Lung Transplant. 30(6), 601-611 (2011).
23. Mills RM, Naftel DC, Kirklin JK et al. Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database. J. Heart Lung Transplant. 16(8), 813-821 (1997).
24. Raichlin E, Edwards BS, Kremers WK et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J. Heart Lung Transplant. 28(4), 320-327 (2009).
25. Haddad F, Fisher P, Pham M et al. Right ventricular dysfunction predicts poor outcome following hemodynamically compromising rejection. J. Heart Lung Transplant. 28(4), 312-319 (2009).
26. Michaels PJ, Espejo ML, Kobashigawa J et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J. Heart Lung Transplant. 22(1), 58-69 (2003).
27. Wu GW, Kobashigawa JA, Fishbein MC et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J. Heart Lung Transplant. 28(5), 417-422 (2009).
28. Stehlik J, Starling R, Movsesian M et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J. Heart Lung Transplant. 25(12), 1402-1409 (2006).
29. Hamour IM, Burke MM, Bell AD, Panicker MG, Banerjee R, Banner NR. Limited utility of endomyocardial biopsy in the first year after heart transplantation. Transplantation 85(7), 969-974 (2008).
30. Saraiva F, Matos V, Gonçalves L, Antunes M, Providência LA. Complications of endomyocardial biopsy in heart transplant patients: a retrospective study of 2117 consecutive procedures. Transplant. Proc. 43(5), 1908-1912 (2011).
31. Evans RW, Williams GE, Baron HM et al. The economic implications of noninvasive molecular testing for cardiac allograft rejection. Am. J. Transplant. 5(6), 1553-1558 (2005).
32. Yang HM, Lai CK, Gjertson DW et al. Has the 2004 revision of the International Society of Heart and Lung Transplantation grading system improved the reproducibility of the diagnosis and grading of cardiac transplant rejection? Cardiovascular Pathology. 18(4), 198-204 (2009).
33. Angelini A, Andersen CB, Bartoloni G et al. A web-based pilot study of inter-pathologist reproducibility using the ISHLT 2004 working formulation for biopsy diagnosis of cardiac allograft rejection: the European experience. J. Heart Lung Transplant. 30(11), 1214-1220 (2011).
34. Eleid MF, Caracciolo G, Cho EJ et al. Natural history of left ventricular mechanics in transplanted hearts. JACC Cardiovasc. Imaging 3(10), 989-1000 (2010).
35. Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J. Cardiovasc. Magn. Reson. 11(1), 7 (2009).
36. Schoels M, Dengler T, Richter R, Meuer S, Giese T. Detection of cardiac allograft rejection by real-time PCR analysis of circulating mononuclear cells. Clin. Transplant. 18(5), 513-517 (2004).
37. Horwitz PA. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 110(25), 3815-3821 (2004).
38. Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6(1), 150-160 (2006).
39. Starling R, Deng M, Kobashigawa J, Wohlgemuth J, Rosenberg S, Mehra M. The influence of corticosteroids on the alloimmune molecular signature for cardiac allograft rejection. J. Heart Lung Transplant. 24(2), S65-S66 (2005).
40. Starling RC, Pham M, Valantine H et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J. Heart Lung Transplant. 25(12), 1389-1395 (2006).
41. Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J. Heart Lung Transplant. 26(8), 808-814 (2007).
42. Pham MX, Teuteberg JJ, Kfoury AG et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N. Engl. J. Med. 362(20), 1890-1900 (2010).
43. Kubo SH, Naftel DC, Mills RM et al. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J. Heart Lung Transplant. 14(3), 409-418 (1995).
44. Mehra MR, Parameshwar J. Gene expression profiling and cardiac allograft rejection monitoring: is IMAGE just a mirage? J. Heart Lung Transplant. 29(6), 599-602 (2010).
45. Lin D, Hollander Z, Ng RT et al. Whole blood genomic biomarkers of acute cardiac allograft rejection. J. Heart Lung Transplant. 28(9), 927-935 (2009).
46. Hollander Z, Lin D, Chen V et al. Whole blood biomarkers of acute cardiac allograft rejection: double-crossing the biopsy. Transplantation 90(12), 1388-1393 (2010).
47. Chin C, Chen G, Sequeria F et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J. Heart Lung Transplant. 30(2), 158-163 (2011).
48. Hodges AM, Lyster H, McDermott A et al. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation 93(6), 650-656 (2012).
49. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 86(3), 384-390 (2008).
50. Cadeiras M, Bayern M, Burke E et al. Gene expression profiles of patients with antibody-mediated rejection after cardiac transplantation. J. Heart Lung Transplant. 27(8), 932-934 (2008).
51. Yabu JM, Higgins JP, Chen G, Sequeira F, Busque S, Tyan DB. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 91(3), 342-347 (2011).
52. Rahimi S, Qian Z, Layton J, Fox-Talbot K, Baldwin WM, Wasowska BA. Non-complement-and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am. J. Transplant. 4(3), 326-334 (2004).
53. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467(7319), 1061-1073 (2010).
54. Pang AW, MacDonald JR, Pinto D et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol. 11(5), R52 (2010).
55. Smith NL, Felix JF, Morrison AC et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ. Cardiovasc. Genet. 3(3), 256-266 (2010).
56. Ehret GB, Munroe PB, Rice KM et al.; International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478(7367), 103-109 (2011).
57. Abbas AK, Lichtman AH, Pillai S. Cytokines. In: Cellular and Molecular Immunology (6th Edition). Saunders/Elsevier, Philadelphia, PA, USA, 267-302 (2011).
58. Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation 89(5), 2421-2432 (1994).
59. Girnita DM, Webber SA, Zeevi A. Clinical impact of cytokine and growth factor genetic polymorphisms in thoracic organ transplantation. Clin Lab Med. 28(3), 423-440 (2008).
60. Turner D, Grant SC, Yonan N et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 64(5), 776-779 (1997).
61. Awad MR, Webber S, Boyle G et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J. Heart Lung Transplant. 20(6), 625-630 (2001).
62. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl Acad. Sci. USA 94(7), 3195-3199 (1997).
63. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24(1), 1-8 (1997).
64. Girnita DM, Brooks MM, Webber SA et al. Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation 85(11), 1632-1639 (2008).
65. Benza RL, Coffey CS, Pekarek DM et al. Transforming growth factor-beta polymorphisms and cardiac allograft rejection. J. Heart Lung Transplant. 28(10), 1057-1062 (2009).
66. Cattaneo D, Baldelli S, Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am. J. Transplant. 8(7), 1374-1383 (2008).
67. de Denus S, Zakrzewski M, Barhdadi A et al. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J. Heart Lung Transplant. 30(3), 326-331 (2011).
68. Lee SJ, Usmani KA, Chanas B et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13(8), 461-472 (2003).
69. Jacobson PA, Oetting WS, Brearley AM et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a Multicenter Kidney Transplant Consortium. Transplantation 91(3), 300-308 (2011).
70. Kniepeiss D, Renner W, Trummer O et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin. Transplant. 25(1), 146-150 (2011).
71. Gijsen V, Mital S, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant. 30(12), 1352-1359 (2011).
72. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin. Transplant. 10(1 Pt 2), 77-84 (1996).
73. Ohmann EL, Burckart GJ, Brooks MM et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J. Heart Lung Transplant. 29(5), 509-516 (2010).
74. Colobran R, Casamitjana N, Roman A et al. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun. 10(3), 254-259 (2009).
75. Li H, Xie HY, Zhou L et al. Copy number variation in CCL3L1 gene is associated with susceptibility to acute rejection in patients after liver transplantation. Clin. Transplant. 26(2), 314-321 (2011).
76. Sarwal MM, Benjamin J, Butte AJ, Davis MM, Wood K, Chapman J. Transplantomics and biomarkers in organ transplantation: a report from the first international conference. Transplantation 91(4), 379-382 (2011).
77. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 149(3), 515-524 (2012).
78. Anglicheau D, Sharma VK, Ding R et al. MicroRNA expression profiles predictive of human renal allograft status. Proc. Natl Acad. Sci. USA 106(13), 5330-5335 (2009).
79. Kienzl-Wagner K, Pratschke J, Brandacher G. Proteomics-a blessing or a curse? Application of proteomics technology to transplant medicine. Transplantation 92(5), 499-509 (2011).
80. Freue GVC, Sasaki M, Meredith A et al. Proteomic signatures in plasma during early acute renal allograft rejection. Mol. Cell Proteomics. 9(9), 1954-1967 (2010).
81. Zhang Q, Reed EF. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr. Opin. Immunol. 22(5), 682-688 (2010).
82. Reinsmoen NL, Lai CH, Heidecke H et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor hla antibody negative patients. Transplantation 90(12), 1473-1477 (2010).
83. Li L, Wadia P, Chen R et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and antibodyome measures. Proc. Natl Acad. Sci. USA 106(11), 4148-4153 (2009).